[Participation of Sphingolipids in the Pathogenesis of Atherosclerosis]

A V Alessenko1, D A Zateyshchikov2, A Т Lebedev3

  • 1N.M. Emanuel Institute of Biochemical Physics.

Kardiologiia
|August 10, 2019
PubMed

Insights

Sphingolipids, like ceramides and sphingosine-1-phosphate (S-1-P), are crucial in cardiovascular disease development. Monitoring their levels may aid early diagnosis of heart issues and hypertension.

Area of Science:

  • Biochemistry
  • Cardiology
  • Metabolomics

Background:

  • Lipid metabolism disorders are primary risk factors for cardiovascular diseases (CVD).
  • Sphingolipids, including ceramides and sphingosine-1-phosphate (S-1-P), intersect with cholesterol biosynthesis and impact cellular apoptosis.
  • Elevated ceramides and reduced S-1-P are implicated in cardiovascular pathologies like atherosclerosis and hypertension.

Purpose of the Study:

  • To investigate the role of sphingolipids in cardiovascular disease pathogenesis.
  • To explore the potential of sphingolipid levels as biomarkers for early diagnosis of cardiac ischemia and hypertension.

Main Methods:

  • Analysis of lipid metabolism pathways, focusing on cholesterol and sphingolipid biosynthesis.
  • Measurement of ceramide, sphingosine, and S-1-P levels in biological samples.
  • Chromatography-mass spectrometry proposed for sphingolipid quantification.

Main Results:

  • Ceramides are enriched in atherosclerotic lesions and increase during cardiac ischemia/reperfusion and in hypertension.
  • S-1-P levels decrease significantly during ischemia and myocardial infarction, despite its cardioprotective role.
  • S-1-P is a key component of high-density lipoproteins (HDL), influencing their function.

Conclusions:

  • Altered sphingolipid metabolism, specifically increased ceramides and decreased S-1-P, contributes to atherosclerosis development.
  • Measuring sphingolipid levels in blood plasma shows promise for early diagnosis of cardiac ischemia and arterial hypertension.
  • Targeting S-1-P receptors represents a potential therapeutic strategy for cardiovascular diseases.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
335
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
957
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.2K
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
738
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
590
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
479